Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.

Archives of medical research - 1 Jan 2013

Lee Ju-Han, Kim Younghye, Choi Jung-Woo, Kim Young-Sik

Abstract excerpt

BACKGROUND AND AIMS: Plasminogen activator inhibitor type 1 (PAI-1) is associated with poor prognosis in breast cancer. Transcriptional expression of the PAI-1 can be controlled by PAI-1 promoter 4G/5G polymorphism. However, the significance of PAI-1 promoter 4G/5G polymorphism in breast cancer patients is contentious. To address this controversy, we conducted a meta-analysis for the relationships between PAI-1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Odds Ratio

Share to Plasminogen Activator Inhibitor 1

Share to Polymorphism, Genetic

Share to Promoter Regions, Genetic

Share to White People

Source

Identifiers

PMID: 23291383
DOI: 10.1016/j.arcmed.2012.12.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.PMID 23291383Read ↗

Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.Semantic proximity Read ↗

PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.Semantic proximity Read ↗

Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.Semantic proximity Read ↗

Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast.Semantic proximity Read ↗

Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.Semantic proximity Read ↗

Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.Semantic proximity Read ↗

PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.Semantic proximity Read ↗

The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.Semantic proximity Read ↗

What is the impact of plasminogen activator inhibitor type 1 (PAI-1) gene polymorphism on gynecological malignancies: a retrospective studySemantic proximity Read ↗

Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.